Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 1/2007

01-01-2007 | Review Article

Patient Adherence to Osteoporosis Medications

Problems, Consequences and Management Strategies

Authors: Dr Alexandra Papaioannou, Courtney C. Kennedy, Lisa Dolovich, Elaine Lau, Jonathan D. Adachi

Published in: Drugs & Aging | Issue 1/2007

Login to get access

Abstract

Adherence to osteoporosis medications is relatively poor. Approximately 20–30% of patients taking daily or weekly treatments may suspend their treatment within 6 to 12 months of initiating therapy. Patients with poor adherence increase their risk of osteoporotic fractures and hospitalisation. The majority of patients who discontinue therapy appear to do so because of drug-induced adverse effects. Fear of adverse effects or other health risks is another commonly cited reason for discontinuing therapy. Factors associated with medication adherence include fractures, regular exercise, female sex, fewer non-osteoporosis medications and co-morbidities, early menopause, willingness to take medications, awareness of osteoporosis status based on a diagnostic test, anti-inflammatory therapy and corticosteroid therapy. Factors associated with non-adherence include adverse effects, pain and being unsure about bone mineral density (BMD) test results. Bisphosphonates, a common class of drugs for treating osteoporosis, have specific administration requirements (e.g. fasting, remaining upright and not ingesting other medications concomitantly). Patient surveys indicate that 12–18% of patients report non-compliance with at least one administration rule. Strategies to increase adherence include reducing administration frequency to weekly or monthly, monitoring patients with bone markers and BMD testing, providing adequate instructions, practitioner feedback and support, and educational materials and sessions. Future studies are needed regarding strategies to increase adherence to osteoporosis medications.
Literature
1.
Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991; 90(1): 107–110
2.
Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999; 10(4): 259–64PubMedCrossRef
3.
Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005; 16Suppl. 2: S3–7PubMedCrossRef
4.
Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35(2): 375–82PubMedCrossRef
5.
Adachi JD, Olszynski WP, Hanley DA, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000; 29(4): 228–51PubMedCrossRef
6.
Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19(6): 893–9PubMedCrossRef
7.
Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12(12): 989–95PubMedCrossRef
8.
Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20(7): 1185–94PubMedCrossRef
9.
Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone 2004; 35(5): 1029–37PubMedCrossRef
10.
Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12(1): 24–35PubMedCrossRef
11.
Ross PD. Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med 1996; 156(13): 1399–411PubMedCrossRef
12.
Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151(10): 2026–32PubMedCrossRef
13.
National Osteoporosis Foundation. America’s bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, 2002
14.
Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23(4): 570–8PubMedCrossRef
15.
Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005; 6: 39PubMedCrossRef
16.
17.
Sackett DL. Introduction. In: Sackett DL, editor. Compliance with therapeutic regimens. Baltimore MD): Johns Hopkins University Press, 1976
18.
Haynes RB, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005; 4: CD000011
19.
Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60(7): 657–65PubMed
20.
Cranney A, Tugwell P, Wells G, et al. Meta-analyses of therapies for postmenopausal osteoporosis: I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002; 23(4): 496–507PubMedCrossRef
21.
Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis: III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23(4): 517–23PubMedCrossRef
22.
Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23(4): 508–16PubMedCrossRef
23.
Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001; 12(2): 140–51PubMedCrossRef
24.
Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis: IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23(4): 524–8PubMedCrossRef
25.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–33PubMedCrossRef
26.
Cranney A, Wells GA. Hormone replacement therapy for postmenopausal osteoporosis. Clin Geriatr Med 2003; 19(2): 361–70PubMedCrossRef
27.
Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15(12): 1003–8PubMedCrossRef
28.
Goettsch WG, Penning F, Erkens JE, et al. Persistent bisphosphonate usage reduces the risk of hospitalizations for osteoporotic fractures [abstract]. J Bone Miner Res 2005; 20Suppl. 1: S278
29.
Weycker D, Macarios D, Oster G. Adherence with drug therapy and risk of fracture among women with postmenopausal osteoporosis [abstract]. J Bone Miner Res 2005; 20Suppl. 1: S383
30.
Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2005; 38(6): 922–8PubMedCrossRef
31.
Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study [abstract]. Calcif Tissue Int 2003, 72
32.
Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologie therapy for osteoporosis. Osteoporos Int 2003; 14(12): 965–8PubMedCrossRef
33.
Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11(1): 83–91PubMedCrossRef
34.
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535–41PubMedCrossRef
35.
Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333(22): 1437–43PubMedCrossRef
36.
Ho AY, Kung AW. Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Ann Pharmacother 2005; 39(9): 1428–33PubMedCrossRef
37.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999; 282(7): 637–45PubMedCrossRef
38.
Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288(1): 49–57PubMedCrossRef
39.
Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348(9024): 383–6PubMedCrossRef
40.
Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 1987; 8(1): 12–9PubMedCrossRef
41.
Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115(3): 209–16PubMedCrossRef
42.
Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003; 14(3): 259–62PubMed
43.
Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5(12): 859–62PubMed
44.
Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006; 17(6): 914–21PubMedCrossRef
45.
Zanchetta J, Hakim C, Lombas C. Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Current Therapeutic Research 2004; 6: 470–80CrossRef
46.
Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003; 14(10): 808–13PubMedCrossRef
47.
Steel SA, Albertazzi P, Howarth EM, et al. Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis. Climacteric 2003; 6(2): 96–103PubMed
48.
Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. J Managed Care Pharm 1998; 4(5): 488–92
49.
Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26(2): 245–56PubMedCrossRef
50.
Carnevale V, Nieddu L, Romagnoli E, et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos Int 2005; 17(3): 478–83PubMedCrossRef
51.
Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21(9): 1453–60PubMedCrossRef
52.
McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48(3): 271–87PubMedCrossRef
53.
Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 Suppl.): Sl–34
54.
55.
Aki S, Eskiyurt N, Akarirmak U, et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J 2003; 44(6): 961–7PubMed
56.
Lombas C, Hakim C, Zanchetta J. Compliance with alendronate treatment in an osteoporosis clinic [abstract]. J Bone Miner Res 2001; 15: S529
57.
Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999; 6(4): 282–9PubMedCrossRef
58.
den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000; 95(4): 507–12CrossRef
59.
Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165(20): 2414–9PubMedCrossRef
60.
Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80(7): 856–61PubMedCrossRef
61.
Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000 Dec; 22(12): 1433–42PubMedCrossRef
62.
Rizzoli R, Greenspan SL, Bone G, et al. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17(11): 1988–96PubMedCrossRef
63.
64.
Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003; 14(5): 437–41PubMedCrossRef
65.
Kendler D, Kung AW, Fuleihan G, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004; 48(3): 243–51PubMedCrossRef
66.
Weiss M, Vered I, Foldes AJ, et al. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 2005; 17(2): 143–9PubMed
67.
Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002; 24(11): 1871–86PubMedCrossRef
68.
69.
Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006 May; 65(5): 654–61PubMedCrossRef
70.
Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21(3): 391–401PubMedCrossRef
71.
Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006; 38 (4 Suppl. 1): S2–6PubMedCrossRef
72.
Emkey R. BNSLRC. BALTO I: women treated for osteoporosis rate preference and convenience for once-monthly ibandronate versus once-weekly alendronate [abstract]. J Bone Miner Res 2005; 20Suppl. 1: S416
73.
Blalock SJ, DeVellis BM, Patterson CC, et al. Effects of an osteoporosis prevention program incorporating tailored educational materials. Am J Health Promot 2002; 16(3): 146–56PubMedCrossRef
74.
Chapurlat RD, Cummings SR. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness? Osteoporos Int 2002; 13(9): 738–44PubMedCrossRef
75.
Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89(3): 1117–23PubMedCrossRef
76.
Rijcken CA, Tobi H, Vergouwen AC, et al. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients’ compliance by using computerised pharmacy data. Pharmacoepidemiol Drug Saf 2004; 13(6): 365–70PubMedCrossRef
77.
Pilon D, Castilloux AM, LeLorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 2001; 97(1): 97–100PubMedCrossRef
78.
Morgan SG, Yan L. Persistence with hypertension treatment among community-dwelling BC seniors. Can J Clin Pharmacol 2004; 11(2): e267–73PubMed
79.
Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288(4): 462–7PubMedCrossRef
80.
Haynes RB, Taylor DW, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension 1980; 2(6): 757–64PubMedCrossRef
81.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67–74PubMedCrossRef
82.
Royal Pharmaceutical Society of Great Britain. From compliance to concordance: towards shared goals in medicine taking. London: Royal Pharmaceutical Society of Great Britain, 1997
83.
MacLaughlin EJ, MacLaughlin AA, Snella KA, et al. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy 2005; 25(3): 379–86PubMedCrossRef
84.
Elliott ME, Meek PD, Kanous NL, et al. Pharmacy-based bone mass measurement to assess osteoporosis risk. Ann Pharmacother 2002; 36(4): 571–7PubMedCrossRef
85.
Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337(10): 670–6PubMedCrossRef
86.
Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354(7): 669–83PubMedCrossRef
87.
Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004; 19(3): 370–8PubMedCrossRef
88.
Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330(7498): 1003PubMedCrossRef
89.
Prince RL, Devine A, Dhaliwal SS, et al. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006; 166(8): 869–75PubMedCrossRef
90.
Mastaglia SR, Pellegrini GG, Mandalunis PM, et al. Vitamin D insufficiency reduces the protective effect of bisphosphonate on ovariectomy-induced bone loss in rats. Bone 2006; 39(4): 837–44PubMedCrossRef
91.
Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996; 51(2): 145–7PubMedCrossRef
92.
French MR, Moore K, Vernace-Inserra F, et al. Factors that influence adherence to calcium recommendations. Can J Diet Pract Res 2005; 66(1): 25–9PubMedCrossRef
93.
Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163(18): 2165–72PubMedCrossRef
94.
Papaioannou A, Giangregorio L, Kvern B, et al. The osteoporosis care gap in Canada. BMC Musculoskelet Disord 2004; 5: 11PubMedCrossRef
Metadata
Title
Patient Adherence to Osteoporosis Medications
Problems, Consequences and Management Strategies
Authors
Dr Alexandra Papaioannou
Courtney C. Kennedy
Lisa Dolovich
Elaine Lau
Jonathan D. Adachi
Publication date
01-01-2007
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 1/2007
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200724010-00003

Other articles of this Issue 1/2007

Drugs & Aging 1/2007 Go to the issue

Original Research Article

Effects of Statins on Cognitive Function in Patients with Alzheimer’s Disease in Galantamine Clinical Trials

Therapy In Practice

Post-Herpetic Neuralgia in Older Adults

From the World Literature

Gerontology Forum

Original Research Article

Elderly Medical Patients Treated with Prophylactic Dosages of Enoxaparin

Review Article

Management of Gout in Older Adults
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits